

## **pan-Canadian Oncology Drug Review Stakeholder Feedback on a pCODR Expert Review Committee Initial Recommendation (Provincial Advisory Group [PAG])**

### **Decitabine and Cedazuridine (Inqovi) for Myelodysplastic Syndromes**

September 22, 2021

### 3 Feedback on pERC Initial Recommendation

Name of the Drug and Indication(s):	Decitabine-Cedazuridine for MDS
Eligible Stakeholder Role	
Organization Providing Feedback	Provincial Advisory Group (PAG)

#### 3.1 Comments on the Initial Recommendation

a) Please indicate if the stakeholder agrees, agrees in part, or disagrees with the initial recommendation:

- Agrees
  Agrees in part
  Disagrees

PAG agrees in part with the initial recommendation pending clarification on the cost-savings comments outlined in 3.1 b).

b) Please provide editorial feedback on the initial recommendation to aid in clarity. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity
Table 1 Reimbursement Conditions and Reasons	Pricing	Row 5	PAG is requesting the following editorial revision “ <i>Decitabine and cedazuridine should be negotiated to provide cost savings to the CADTH-participating-drug programs...</i> ”
Table 2 Summary of Economic Evaluation	CADTH reanalysis results	Row 13	PAG is requesting the addition of a willingness to pay threshold be stated here to put into context what QALY is achieved with a 15% price reduction.

#### 3.2 Comments Related to Eligible Stakeholder Provided Information

Notwithstanding the feedback provided in part a) above, please indicate if the stakeholder would support this initial recommendation proceeding to final recommendation (“early conversion”), which would occur two business days after the end of the feedback deadline date.

- Support conversion to final recommendation.  
 Recommendation does not require reconsideration by pERC.
- Do not support conversion to final recommendation.  
 Recommendation should be reconsidered by pERC.

If the eligible stakeholder does not support conversion to a final recommendation, please provide feedback on any issues not adequately addressed in the initial recommendation based on any information provided by the stakeholder during the review.

Please note that new evidence will be not considered at this part of the review process, however, it may be eligible for a resubmission.

Additionally, if the eligible stakeholder supports early conversion to a final recommendation; however, the stakeholder has included substantive comments that requires further interpretation of the evidence, the criteria for early conversion will be deemed to have not been met and the initial recommendation will be returned to pERC for further deliberation and reconsideration at the next possible pERC meeting.